Trial Profile
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Aug 2023
Price :
$35
*
At a glance
- Drugs Teprotumumab (Primary)
- Indications Graves ophthalmopathy
- Focus Therapeutic Use
- Sponsors Horizon Pharma; River Vision Development Corp
- 18 Jun 2023 Results of pooled analysis from European Study Sites Participating in the Phase 2, OPTIC (Phase 3) and OPTIC-X trials , presented at the 105th Annual Meeting of the Endocrine Society
- 01 Jul 2022 Results of post hoc analysis from NCT01868997 and NCT03298867 evaluating variability in the time taken to manifest a clinically significant response to teprotumumab, published in the Eye
- 11 Jun 2022 According to a Horizon Therapeutics media release, pooled results of this trial and NCT03298867 trial were presented as part of the annual conference of the Endocrine Society, ENDO 2022.